Nervgen Pharma (NGEN) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $1.62, +3.51% vs the prior close of $1.57.
- Volume 475.20K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
NGEN jumps 3.5% to $1.62. Closed at $1.62, +3.51% vs the prior close of $1.57. Day range $1.55–$1.66, opened at $1.59.
NGEN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — NGEN jumps 3.5% to $1.62
- Closed at $1.62, +3.51% vs the prior close of $1.57. Day range $1.55–$1.66, opened at $1.59.
- Volume was 475.20K shares, 0.9x its 50-day average of 533.23K.
- Price is -16.8% vs its 50-day average ($1.95) and -47.3% vs its 200-day average ($3.07).
- 52-week range $1.55–$6.30; today's close sits at 1% of that range, 74.3% below the 52-week high.
Oct 14, 2026 — NGEN slides 4.0% to $1.57, a 52-week low on 2.5x normal volume
- Closed at $1.57, -3.99% vs the prior close of $1.63. Day range $1.55–$1.65, opened at $1.65.
- Volume was 1.30M shares, 2.5x its 50-day average of 514.51K — unusually heavy trading.
- Price is -19.6% vs its 50-day average ($1.95) and -49.4% vs its 200-day average ($3.09).
- 52-week range $1.55–$6.30; today's close sits at 0% of that range, 75.2% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — NGEN slides 5.8% to $1.63, a 1-month low, 3 down days in a row
- Closed at $1.63, -5.78% vs the prior close of $1.73. Day range $1.62–$1.79, opened at $1.74.
- Volume was 506.40K shares, 1.0x its 50-day average of 509.14K.
- Price is -16.4% vs its 50-day average ($1.95) and -47.6% vs its 200-day average ($3.11).
- 52-week range $1.58–$6.30; today's close sits at 1% of that range, 74.1% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — NGEN ends flat (+0.0%) to $1.73
- Closed at $1.73, +0.00% vs the prior close of $1.73. Day range $1.71–$1.79, opened at $1.75.
- Volume was 220.50K shares, 0.4x its 50-day average of 510.72K — lighter than usual.
- Price is -11.3% vs its 50-day average ($1.95) and -44.7% vs its 200-day average ($3.13).
- 52-week range $1.58–$6.30; today's close sits at 3% of that range, 72.5% below the 52-week high.
Oct 9, 2026 — NGEN dips 1.1% to $1.73, a 1-month low
- Closed at $1.73, -1.14% vs the prior close of $1.75. Day range $1.71–$1.80, opened at $1.75.
- Volume was 293.20K shares, 0.6x its 50-day average of 509.27K — lighter than usual.
- Price is -11.1% vs its 50-day average ($1.95) and -45.0% vs its 200-day average ($3.14).
- 52-week range $1.58–$6.30; today's close sits at 3% of that range, 72.5% below the 52-week high.
Oct 8, 2026 — NGEN rises 0.6% to $1.75
- Closed at $1.75, +0.57% vs the prior close of $1.74. Day range $1.72–$1.81, opened at $1.74.
- Volume was 288.90K shares, 0.6x its 50-day average of 510.42K — lighter than usual.
- Price is -10.0% vs its 50-day average ($1.94) and -44.6% vs its 200-day average ($3.16).
- 52-week range $1.58–$6.30; today's close sits at 4% of that range, 72.2% below the 52-week high.
Oct 7, 2026 — NGEN dips 0.6% to $1.74, a 1-month low
- Closed at $1.74, -0.57% vs the prior close of $1.75. Day range $1.73–$1.78, opened at $1.78.
- Volume was 231.50K shares, 0.5x its 50-day average of 513.50K — lighter than usual.
- Price is -10.4% vs its 50-day average ($1.94) and -45.2% vs its 200-day average ($3.17).
- 52-week range $1.58–$6.30; today's close sits at 3% of that range, 72.4% below the 52-week high.
Oct 6, 2026 — NGEN slides 3.3% to $1.75, a 1-month low
- Closed at $1.75, -3.31% vs the prior close of $1.81. Day range $1.73–$1.82, opened at $1.81.
- Volume was 297.80K shares, 0.6x its 50-day average of 515.20K — lighter than usual.
- Price is -9.7% vs its 50-day average ($1.94) and -45.1% vs its 200-day average ($3.19).
- 52-week range $1.58–$6.30; today's close sits at 4% of that range, 72.2% below the 52-week high.
Oct 5, 2026 — NGEN rises 1.7% to $1.81
- Closed at $1.81, +1.69% vs the prior close of $1.78. Day range $1.78–$1.88, opened at $1.78.
- Volume was 441.00K shares, 0.9x its 50-day average of 517.75K.
- Price is -6.5% vs its 50-day average ($1.94) and -43.5% vs its 200-day average ($3.20).
- 52-week range $1.58–$6.30; today's close sits at 5% of that range, 71.3% below the 52-week high.
Oct 2, 2026 — NGEN rises 1.1% to $1.78
- Closed at $1.78, +1.14% vs the prior close of $1.76. Day range $1.74–$1.90, opened at $1.78.
- Volume was 403.60K shares, 0.8x its 50-day average of 519.02K.
- Price is -7.9% vs its 50-day average ($1.93) and -44.6% vs its 200-day average ($3.21).
- 52-week range $1.58–$6.30; today's close sits at 4% of that range, 71.7% below the 52-week high.
NGEN latest news & SEC filings
Every SEC filing by or about NGEN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 25, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 24, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 13, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 2, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade NGEN
- How much it moves: over the last 20 sessions the average daily move was 3.19% (largest 9.7%). That is a volatile stock.
- Liquidity: about 481.90K shares (≈$780.68K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.62 vs a range of $1.55–$6.30 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Sep 25, 2026; 6-K Sep 24, 2026; 6-K Aug 13, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
NGEN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 1.59 | 1.66 | 1.55 | 1.62 | 475.20K |
| Oct 14, 2026 | 1.65 | 1.65 | 1.55 | 1.57 | 1.30M |
| Oct 13, 2026 | 1.74 | 1.79 | 1.62 | 1.63 | 506.40K |
| Oct 12, 2026 | 1.75 | 1.79 | 1.71 | 1.73 | 220.50K |
| Oct 9, 2026 | 1.75 | 1.80 | 1.71 | 1.73 | 293.20K |
| Oct 8, 2026 | 1.74 | 1.81 | 1.72 | 1.75 | 288.90K |
| Oct 7, 2026 | 1.78 | 1.78 | 1.73 | 1.74 | 231.50K |
| Oct 6, 2026 | 1.81 | 1.82 | 1.73 | 1.75 | 297.80K |
| Oct 5, 2026 | 1.78 | 1.88 | 1.78 | 1.81 | 441.00K |
| Oct 2, 2026 | 1.78 | 1.90 | 1.74 | 1.78 | 403.60K |
| Oct 1, 2026 | 1.92 | 1.92 | 1.73 | 1.76 | 1.05M |
| Sep 30, 2026 | 1.91 | 1.98 | 1.90 | 1.91 | 548.40K |
| Sep 29, 2026 | 1.86 | 1.96 | 1.84 | 1.92 | 556.80K |
| Sep 28, 2026 | 1.89 | 1.99 | 1.88 | 1.88 | 525.40K |
| Sep 25, 2026 | 2.00 | 2.01 | 1.91 | 1.94 | 343.20K |
| Sep 24, 2026 | 1.98 | 2.02 | 1.91 | 2.02 | 316.90K |
| Sep 23, 2026 | 2.05 | 2.09 | 1.96 | 1.96 | 536.30K |
| Sep 22, 2026 | 2.00 | 2.10 | 1.99 | 2.07 | 223.50K |
| Sep 21, 2026 | 2.06 | 2.06 | 1.96 | 1.99 | 473.60K |
| Sep 18, 2026 | 2.27 | 2.27 | 2.04 | 2.05 | 607.50K |
About Nervgen Pharma
Nervgen Pharma (NGEN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in VANCOUVER, British Columbia, Canada. State of incorporation: British Columbia, Canada. Fiscal year ends December 31. SEC CIK 1751912.
NGEN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
NGEN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
NGEN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on NGEN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.